webinar recording available - register to watch

ASCO '23 Preview: Key trials with high clinical and commercial impact

The annual American Society of Clinical Oncology (ASCO) conference will take place June 2-6, 2023, with a profusion of exciting clinical results to be presented. Join us for a review of some of the results that are expected to have a near-term impact on patient care and the pharmaceutical industry, including potentially practice-changing results in non-small cell lung cancer, multiple myeloma, Hodgkin lymphoma, emerging / evolving biomarker populations, and more!

A panel of experts will share their perspectives on the impact this data will have on clinical practice and commercial implications for pharma and the financial sector.

watch now
watch the webinar

No cost to register, subject to confirmation

By registering for this event, you accept that you may receive direct communication from the sponsor(s).

If you are experiencing problems with your registration, please try the Zoom registration page.

Jay Grisolano

Jay Grisolano

Principal, Oncology & Specialty Therapeutics, Cerner Enviza, an Oracle Company

Dr. Grisolano has nearly two decades of strategic consulting experience with a focus on custom engagements in the therapeutic areas of oncology and rare disease. He brings scientific, clinical, and commercial expertise to support the needs of clients.

He leads a team of consultants that partner with clients to provide commercially-oriented insights to complex business questions, ranging from market access drivers/barriers to sales forecasts indicative of commercial potential.

Kelly Clapp

Kelly Clapp

Engagement Manager, Oncology & Specialty Therapeutics, Cerner Enviza, an Oracle Company

Dr. Clapp has over 7 years of consulting experience focused in oncology, leading consulting engagements in the area of clinical development strategy and planning for biotech and pharma clients.

She leads Cerner Enviza’s Future Trends & Insights offer, which provides an understanding of development trends and implications across global oncology markets.

Brad Loncar

Brad Loncar

CEO, Loncar Investments

Brad is a biotechnology industry investor and CEO of Loncar Investments. He is the creator of two Nasdaq-listed biotech-focused exchange-traded funds. Brad previously worked in the financial services industry at Franklin Templeton Investments where he was a member of the Management Training Program, and was appointed to serve in a Senior Advisor role at the U.S. Department of the Treasury.

He writes biotechnology commentary at www.LoncarBlog.com, Nasdaq.com, and contributes opinion pieces to Endpoints News.

Deborah Wong

Deborah Wong

Associate Clinical Professor of Medicine, Hematology-Oncology, University of California Los Angeles Medical Center

Dr. Wong is a hematologist/oncologist and Associate Clinical Professor of Medicine at UCLA. Her clinical and research focuses are on novel systemic treatments for patients with advanced solid tumors and on clinical advances for head and neck cancer.

Stephanie Hawthorne

Stephanie Hawthorne

General Manager, Oncology & Specialty Therapeutics, Cerner Enviza, an Oracle Company

Dr. Hawthorne has over 19 years of consulting experience focused in oncology, with in-depth knowledge of a wide range of solid and hematologic tumors. Her expertise bridges the gap between clinical understanding and commercial implications for the pharmaceutical and biotech industry.

She currently leads a team responsible for Cerner Enviza’s CancerMPact® offer, a comprehensive data source for cancer epidemiology and treatment trends for over 30 tumor types across global markets.